Epix to develop new MR agent

MR contrast developer Epix Medical will begin development of a molecularly-targeted imaging agent designed to detect thrombus in humans using MRI. The compound, called EP-2104R, is expected to enter human trials in 2004, according to the Cambridge, MA-based firm.

By AuntMinnie.com staff writers
April 1, 2003

Related Reading

Epix contrast agent clears second phase III trial, March 8, 2003

Epix testing of MS-325 moves forward, February 4, 2003

Epix losses continue, MS-325 enrollment completed, October 25, 2002

Epix net loss widens, delays MS-325 NDA, July 26, 2002

Epix shows first-quarter loss, April 24, 2002

Copyright © 2003 AuntMinnie.com

Page 1 of 611
Next Page